Deutsche Bank AG Sells 238,010 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Deutsche Bank AG trimmed its position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 84.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,052 shares of the company’s stock after selling 238,010 shares during the period. Deutsche Bank AG owned about 0.07% of Larimar Therapeutics worth $170,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in shares of Larimar Therapeutics during the fourth quarter valued at about $25,000. Algert Global LLC bought a new position in Larimar Therapeutics in the fourth quarter worth about $47,000. China Universal Asset Management Co. Ltd. bought a new position in Larimar Therapeutics in the fourth quarter worth about $52,000. Aquatic Capital Management LLC bought a new position in Larimar Therapeutics in the fourth quarter worth about $70,000. Finally, SG Americas Securities LLC raised its stake in Larimar Therapeutics by 35.1% in the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock worth $75,000 after buying an additional 5,042 shares in the last quarter. 91.92% of the stock is owned by institutional investors.

Larimar Therapeutics Stock Performance

Shares of LRMR opened at $2.20 on Tuesday. The stock has a market cap of $140.86 million, a PE ratio of -1.91 and a beta of 0.93. Larimar Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $11.20. The firm’s 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $3.33.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). Equities research analysts predict that Larimar Therapeutics, Inc. will post -1.15 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on LRMR. Guggenheim reissued a “buy” rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Citigroup reissued a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. HC Wainwright upped their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 25th. Finally, Robert W. Baird cut their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Larimar Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $19.67.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.